Biocon Ltd. Building a Biotech Powerhouse Case analysis -Rajdeep Desai Introduction: Established in 1978‚ Biocon Limited is Asia’s premier biotechnology company and India’s largest biotechnology company by revenue. It is the only Asian company among the top 25 in global biopharma. Biocon is called as Poster child of Biotech in India. The Group‚ promoted by Ms. Kiran Mazumdar Shaw‚ is a fully-integrated‚ innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and
Premium Clinical trial Biotechnology Pharmaceutical industry
BIOCON 1. Assuming Biocon receives approval for BioMab‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate on the various elements of your action plan. 2. How big is the current and future market opportunity in BIOMAb? The current market opportunity of BIOMAb is limited but the future is going to be bigger. In 2004‚ the 5-year prevalence (number of people diagnosed with cancer and still alive after 5 years) was 375‚000 and the incidence (new cases
Premium Oncology Cancer Chemotherapy
1. Executive Summary 2. Idea Generation: Bangladesh having monsoon weather most of the time our climate is hot and burning. So the use of lotion in that climate is quite irrelevant. In winter the skin looses the smoothness thus it is mandatory to use body lotion. But if we try it in summer then it will be a disaster because of sunburn the skin will become dark and shady. But it is necessary to keep the moisture of body in summer also but due to sunburn we can’t do it. To get rid of this problem
Premium Marketing Brand
CHAPTER [ 10 ] Launching the New Ship of State‚ 1789–1800 PART I: Reviewing the Chapter A. Checklist of Learning Objectives After mastering this chapter‚ you should be able to: [ 1 ]. State why George Washington was pivotal to inaugurating the new federal government. [ 2 ]. Describe the methods and policies Alexander Hamilton used to put the federal government on a sound financial footing. [ 3 ]. Explain how the conflict between Hamilton and Jefferson led to the emergence of the first
Premium United States Constitution John Adams United States
Biocon: Launching a New Cancer Drug in India Section E Group 5 Ankita Khandelwal (255) Bojja Raghavendar Reddy (265) Hitesh Chopra (275) Nikhil Singh Rawat (285) Raghavan K. V. (295) Vaibhav Saxena (305) Situation Analysis: • Biocon is an Indian Drug company that has evolved over the years: ▪ It was an enzyme manufacturer for food industry and developed expertise
Premium Oncology Cancer Chemotherapy
an Indian public-listed company BIOCON Final Project Report Contents Background 3 Subsidiary Companies 4 Products and Services 4 The Auditors report 5 The Director’s Report 6 Accounting Policies 7 Balance sheet 14 Cash flow analysis 18 ANNEXURES 21 Ratio Analysis 23 New Terminologies 29 References 30 Background Established in 1978‚ Biocon is India ’s premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company
Premium Balance sheet Asset Income statement
Biocon Limited 1. Assuming Biocon receives approval for BioMAb‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. Even if the Drug Controller General of India (DCGI) grants permission for BIOMAb in fall 2006‚ Biocon should still conduct phase 3 trials before launching. Both Biocon and Clinigene are new to the industry and strong reputations have yet to be developed. Therefore‚ Biocon must means make sure BIOMAb
Premium Oncology Cancer Chemotherapy
informative white paper about the business of developing new drugs for cancer patients. The content will be turned into a brochure for the public describing the four (4) major issues: economic situation‚ special needs (e.g.‚ health) of the population being served‚ process‚ and benefits of the program. She asked you to include two (2) visuals to illustrate the issues. If you wear pink for Cancer than this is for you! Cancer killer the newest Drug that kills it all. If you have it‚ you had it and went
Premium Cancer KILL Oncology
June 13‚ 2012 India’s Drug Problem India is a world leader in generic drug manufacturing. Their previous policies for food and pharmaceutical patents paved the way for this. Since India’s entry into the World Trade Organization (WTO) in January of 1995 there has been an increasing push for reform of India’s patent laws. While there have been reforms made to the patent laws to comply with WTO regulations‚ they contain vague and somewhat easily exploitable language. It is without question that
Premium Patent Pharmacology Generic drug
strengths of Biocon are * Financial Leverage – Biocon has maintained a constant Debt/ Equity ratio between 0.11-0.12[1] in the last 5 years‚ which gives it a financial leverage‚ thus letting the share holders enjoy the earnings and also makes the organization financially strong. * Skills in Enzymes – Biocon with its recombinant DNA technology has managed to achieve a different share in the industry‚ its products like Insugen from recombinant human DNA‚ BIOMAb EGFR India’s first anti cancer drug
Premium Biotechnology DNA Chemotherapy